1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
Meta-Analyses
You have free access to this content
Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis
Article first published online: 19 JAN 2012
DOI: 10.1111/j.1365-2036.2011.04990.x
© 2012 Blackwell Publishing Ltd
Additional Information
How to Cite
Singal, A. K. and Fontana, R. J. (2012), Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Alimentary Pharmacology & Therapeutics, 35: 674–689. doi: 10.1111/j.1365-2036.2011.04990.x
Publication History
- Issue published online: 20 FEB 2012
- Article first published online: 19 JAN 2012
- Manuscript Accepted: 27 DEC 2011
- Manuscript Revised: 23 DEC 2011
- Manuscript Revised: 5 AUG 2011
- Manuscript Received: 7 JUL 2011
References
- 1. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97–107.
- 2, . Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009; 104: 1693–9.
- 3
- 4, , , et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630–5.
- 5, , , et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263–83.
- 6, . Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661–2.
- 7, , , et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–31.
- 8, , , et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003; 38(Suppl. S4): 262A.
- 9, , , et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109: 908–16.
- 10, , , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.
- 11, , , et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344–9.
- 12, , , et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 207–10.
- 13, . Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000; 33: 301–7.
- 14, , , et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424–32.
- 15, , , et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433–9.
- 16, , , et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002; 74: 1119–24.
- 17, , , et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49–56.
- 18, , , et al. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57–63.
- 19, , , et al. Effect of lamivudine treatment in patients with decompensated cirrhosis due to anti-HBe positive/HBeAg-negative chronic hepatitis B. Clin Transplant 2005; 19: 321–6.
- 20, , , et al. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386–92.
- 21, , , et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13: 334–42.
- 22, , , et al. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol 2007; 5: 1454–61.
- 23, , , et al. A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis. J Gastroenterol Hepatol 2008; 23: 794–803.
- 24, , , et al. Efficcay of entecavir in naive patients with chronic hepatitis B and decompensated liver cirrhosis. J Gastrotroenterol Hepatol 2009; 24: A202.
- 25, , , et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52: S1–21.
- 26, , , et al. Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus. J Korean Med Sci 2005; 20: 821–8.
- 27, , , et al. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J Viral Hepat 2006; 13: 250–5.
- 28, , , et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349–60.
- 29, , , et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009; 29: 420–6.
- 30, , , et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: randomized, open-label study. Hepatology 2011a; 54: 91–100.
- 31, , , et al. Tenofovir disproxil fumarate (TDF), emtricitabine/TDF and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease. Hepatology 2011b; 53: 62–72.
- 32, , , et al. Entecavir therapy for lamivudine resistant HBV cirrhotic patients waiting for OLT: viral and biochemical outcomes at one year. Hepatology 2009; 50: 514A.
- 33, , , et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176–82.
- 34, , , et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–7.
- 35, , , et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464–70.
- 36, , , et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218–29.
- 37, , , et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–51.
- 38, , , et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503–14.
- 39, . Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol 2009; 51: 787–91.
- 40, , , et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421–5.
- 41, , , et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139: 1207–17.
- 42, , , et al. Five-year tenofovir therapy is asssociated with maintained virologic response but significant decline in renal function in HIV-HBV coinfected patients. Hepatology 2009; 50: 506A.
- 43, , , et al. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9: 545–59.
- 44. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185–95.
- 45. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol 2010; 52: 147–9.
- 46, , , et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001–6.
- 47, , , et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776–83.Direct Link:
- 48, , , et al. Telbivudine elevations of CPK in chronic hepatitis B patients in a clinical setting. Hepatology 2010; 52: 533A.